# Arcturus Therapeutics Holdings share price today (Arcturus Therapeutics Holdings Inc., ARCT)

> Arcturus Therapeutics Holdings Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. ARCT · Healthcare · Biotechnology · data as of 4 November 2026. Page: https://www.sectoralpha.in/us/stocks/arct

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $10.87 (+24.7% in a year)
- Revenue (Jun 2026): ₹0.0 B
- Profit (Jun 2026), incl. one-off: ₹0.0 B (one-off item, see below)
- Operating margin: −863.3% (−822.3 points on a year ago)

Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. ## What is the Arcturus Therapeutics Holdings share price today? Arcturus Therapeutics Holdings Inc.'s share price was $10.87 at the close on 4 November 2026. That is 20.2% above its average price over the last 200 trading days. In the last 52 weeks it traded between $6 and $16, and at that close it sat 51% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 1 year the share price moved −21% while the S&P 500 moved +18%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Arcturus Therapeutics Holdings pay? Arcturus Therapeutics Holdings Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Arcturus Therapeutics Holdings on? Arcturus Therapeutics Holdings is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Arcturus Therapeutics Holdings profitable? Arcturus Therapeutics Holdings Inc. posted a net loss of ₹0.02 B in the Jun 2026 quarter. That quarter includes a one-off gain bigger than its revenue, so the comparison with last year does not reflect normal business. The full FY25 year was a loss of ₹0.1 B. That loss is 803.8% of the quarter's revenue. The same quarter a year earlier lost ₹0.01 B. 12 of the last 12 reported quarters were loss-making. Jun 2026 profit was ₹0.0 B. Read this profit with care: at ₹0.0 B it is bigger than the quarter's whole revenue of ₹0.0 B. No business earns more than it takes in from sales, so this is a one-off item (for example a debt settlement, a tax write-back or an asset sale), not money the business earned. The underlying business is running at a −863.3% operating margin. The jump on last year, and any P/E built on this profit, come from the one-off, not from a real turn in earnings. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much revenue does Arcturus Therapeutics Holdings make, and is it growing? Arcturus Therapeutics Holdings Inc. reported ₹0.0 B of revenue in the Jun 2026 quarter, −89.5% on the same quarter a year earlier. Over 4 years it has grown 60.5% a year on average. The last full year, FY25, came in at ₹0.1 B. The last four reported quarters add to ₹0.0 B. FY25 revenue was ₹0.1 B, −46.1% on the year before. Recent pace: the last four quarters grew −77.4% on average, against 60.5% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew −76.0%, against −57.7% a year over the last 8 quarters (rolling over). This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## How much of its sales does Arcturus Therapeutics Holdings keep? Arcturus Therapeutics Holdings Inc.'s operating margin was −863.3% in the Jun 2026 quarter, 822.3 percentage points lower than the same quarter a year ago. Across 5 years it has been between −1,641.3% and 5.9%. The latest quarter is within that range. Why the margin moved: operating margin changed −822.3 percentage points on the year while gross margin changed −487.4 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Arcturus Therapeutics Holdings' profit turning into cash? Arcturus Therapeutics Holdings Inc.'s cash-flow history is too short to judge how much of its profit turns into cash. In FY25 its operations used ₹0.1 B of cash, against −₹0.1 B of profit. After ₹0.0 B of spending on assets, free cash was −₹0.1 B: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. What to look at next: it spends almost nothing on new assets, so the cash goes on running the business. The next section shows the spending figures. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## Where does Arcturus Therapeutics Holdings' cash go? Arcturus Therapeutics Holdings Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent ₹0.0 B on assets over the last 3 years. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: ₹0.0 B over the last 3 years. In short: almost nothing is being spent on new assets, so the cash goes on running the business. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is Arcturus Therapeutics Holdings' P/E ratio, and how does it compare with its own history? Arcturus Therapeutics Holdings Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. The P/E comes back here once profit turns positive. ## Is the Arcturus Therapeutics Holdings business getting better or worse? Arcturus Therapeutics Holdings Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The latest quarter’s profit includes a one-off item bigger than the normal business, so the profit line is shown but does not count in this reading. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Arcturus Therapeutics Holdings earn on its capital? Arcturus Therapeutics Holdings Inc. earned a ROE of −31% in FY25. That is up from a low of −89% in FY21. Its return on capital used (ROIC) is left out: on sales this small it reads −480%, a number that says nothing useful about the business. It comes from a −80.2% net margin and 0.30× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −80.2% net margin × 0.30× asset turnover × 1.27× leverage (assets divided by equity) ≈ −30.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. ## Does Arcturus Therapeutics Holdings have too much debt? Arcturus Therapeutics Holdings Inc. has total debt of ₹0.0 B against shareholder equity of ₹0.2 B as of Jun 2026, so its debt is 0.13× its equity, which is very little. Year by year, that ratio went from 0.30 in FY21 to 0.12 in FY25. So the returns on this page come from the business, not from borrowed money. This company reports in its home currency, not US dollars, so the money charts are left out here. The figures in the text are in that currency (₹); nothing is converted. ## What is the Arcturus Therapeutics Holdings shareholding pattern? 20.9% of Arcturus Therapeutics Holdings Inc.'s tradable shares are in short positions, which are bets that the price will fall, so a large group of traders is betting against it. At normal trading volumes, closing those positions would take about 7.0 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Arcturus Therapeutics Holdings from balance-sheet trouble? For Arcturus Therapeutics Holdings Inc., the Z-score is −0.68. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of −0.68 is inside the danger zone, so the balance sheet is a real risk. ## How does Arcturus Therapeutics Holdings rank in its industry? There is no score against its industry: Arcturus Therapeutics Holdings Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Arcturus Therapeutics Holdings compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Arcturus Therapeutics Holdings in size? Arcturus Therapeutics Holdings is the 170th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: X4 Pharmaceuticals, Inc., Agenus Inc. and Enanta Pharmaceuticals, Inc. Just below it: ARS Pharmaceuticals, Inc., Century Therapeutics, Inc. and vTv Therapeutics Inc. ### Biotechnology companies close in size

1. [X4 Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/xfor) $321 million
2. [Agenus Inc.](https://www.sectoralpha.in/us/stocks/agen) $314 million
3. [Enanta Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/enta) $310 million
4. Arcturus Therapeutics Holdings Inc. $309 million
5. [ARS Pharmaceuticals, Inc.](https://www.sectoralpha.in/us/stocks/spry) $303 million
6. [Century Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/ipsc) $302 million
7. [vTv Therapeutics Inc.](https://www.sectoralpha.in/us/stocks/vtvt) $299 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [Ellomay Capital Ltd.](https://www.sectoralpha.in/us/stocks/ello) $273 million · Utilities - Renewable
2. [BCB Bancorp, Inc.](https://www.sectoralpha.in/us/stocks/bcbp) $272 million · Banks - Regional
3. Arcturus Therapeutics Holdings Inc. $271 million
4. [Outdoor Holding Company](https://www.sectoralpha.in/us/stocks/poww) $271 million · Aerospace & Defense
5. [Hawthorn Bancshares, Inc.](https://www.sectoralpha.in/us/stocks/hwbk) $271 million · Banks - Regional

## What else do people ask about Arcturus Therapeutics Holdings? ### What were Arcturus Therapeutics Holdings's latest quarterly results? Arcturus Therapeutics Holdings Inc. reported revenue of ₹0.0 B and a net loss of ₹0.0 B for the Jun 2026 quarter. The operating margin was −863.3%, 822.3 percentage points lower than a year earlier (as of 4 November 2026). ### What is Arcturus Therapeutics Holdings's market cap? Arcturus Therapeutics Holdings Inc.'s market capitalisation is $309 M at a stock price of $10.87. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 4 November 2026). ### How is Arcturus Therapeutics Holdings performing? Arcturus Therapeutics Holdings Inc.'s latest readings are below. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 4 November 2026). ### Will Arcturus Therapeutics Holdings's stock price go up? This page does not forecast Arcturus Therapeutics Holdings Inc.'s stock price. What it shows instead: the stock price is $10.87. Nobody can reliably say which way a price will move, and this site does not try (as of 4 November 2026). ### Where is Arcturus Therapeutics Holdings in its business cycle? Arcturus Therapeutics Holdings Inc.'s FY25 operating margin was −93.0%, against a 5-year range of −1,641.3% to 5.9%: the middle of its own range, neither a peak nor a low. The latest quarter was −863.3%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 4 November 2026). ### What could break the Arcturus Therapeutics Holdings story? Biggest thing to watch: the price is not yet in a clear uptrend, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 4 November 2026). ### Is Arcturus Therapeutics Holdings a stock worth studying right now? What the numbers show: Arcturus Therapeutics Holdings Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 4 November 2026). This is research, not advice. We’re not SEBI-registered.